BRT

(redirected from TYRO3)
Also found in: Medical, Encyclopedia.

BRT

abbr.
bus rapid transit
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

BRT

abbreviation for
(Telecommunications) be right there
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations
Mentioned in ?
References in periodicals archive ?
TAM receptors (Tyro3, Axl, MerTK) are receptor tyrosine kinases (RTKs) expressed in innate immune cells.
The technology blocks ligand (Gas6) binding, thereby inhibiting TAM (Tyro3, Axl, and Mertk)-mediated activation of cellular processes that may lead to aggressive growth and spread of tumours.
This family of cell surface transmembrane receptors has three members: TYRO3, AXL, and MERTK.
These receptors include scavenger receptors (e.g., CD36, SR1, and macrophage receptor with collagenous structure (MARCO)), low-density lipoprotein (LDL) receptor family members (e.g., LDLR, ApoER2, and VLDL), and three receptor tyrosine kinases (Tyro3, Axl, and Mertk) [5, 26].
(72) Additional receptors reported for ZIKV include T-cell immunoglobulin and mucin domain (TIM1) TYRO3, and AXL.
The DNA breakage surveillance protein Chk1 and the TYRO3 which was required for G1/S transition in breast cancer cell decreased as well.
Another molecule identified as an entry factor for DENV is AXL [14] which belongs to the TYRO3 AXL MER (TAM) family, a group of tyrosine kinase receptors involved in the clearance of apoptotic cells and regulation of innate immunity [15,16].
Soon after it was recognized as a growth factor-like molecule, as it interacted with receptor tyrosine kinases (RTKs) of the TAM family; Tyro3, Axl, and MerTK.
Sitravatinib is an investigational spectrum-selective kinase inhibitor that potently inhibits receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
The technology blocks ligand binding, thereby inhibiting TAM (Tyro3, Axl, and Mertk)-mediated activation of cellular processes that may lead to aggressive growth and spread of tumors.